Kodiak Sciences Inc. $KOD Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lowered its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 76.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,085 shares of the company's stock after selling 26,255 shares during the period. Public Employees Retirement System of Ohio's holdings in Kodiak Sciences were worth $30,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Acadian Asset Management LLC boosted its stake in Kodiak Sciences by 27.0% during the 1st quarter. Acadian Asset Management LLC now owns 1,946,134 shares of the company's stock worth $5,454,000 after purchasing an additional 413,821 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in Kodiak Sciences by 16.3% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,325,707 shares of the company's stock worth $3,719,000 after purchasing an additional 186,180 shares during the period. ICONIQ Capital LLC boosted its stake in Kodiak Sciences by 24.6% during the 1st quarter. ICONIQ Capital LLC now owns 1,266,563 shares of the company's stock worth $3,559,000 after purchasing an additional 249,699 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in shares of Kodiak Sciences by 90.1% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 685,198 shares of the company's stock worth $1,922,000 after acquiring an additional 324,722 shares during the period. Finally, Nantahala Capital Management LLC lifted its stake in shares of Kodiak Sciences by 99.1% in the 1st quarter. Nantahala Capital Management LLC now owns 530,713 shares of the company's stock worth $1,489,000 after acquiring an additional 264,100 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

Kodiak Sciences Trading Up 1.6%

NASDAQ:KOD opened at $14.46 on Thursday. The firm has a 50-day moving average price of $10.64 and a two-hundred day moving average price of $6.24. Kodiak Sciences Inc. has a twelve month low of $1.92 and a twelve month high of $19.39. The company has a market capitalization of $763.78 million, a P/E ratio of -3.81 and a beta of 2.67.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.02). On average, equities research analysts predict that Kodiak Sciences Inc. will post -3.45 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Chardan Capital restated a "neutral" rating and issued a $14.00 target price on shares of Kodiak Sciences in a research note on Monday. Barclays upgraded shares of Kodiak Sciences from an "underweight" rating to an "equal weight" rating and raised their target price for the stock from $7.00 to $17.00 in a research note on Thursday, September 25th. Weiss Ratings restated a "sell (e+)" rating on shares of Kodiak Sciences in a research note on Wednesday. Jefferies Financial Group assumed coverage on shares of Kodiak Sciences in a research note on Monday, September 22nd. They issued a "buy" rating and a $15.00 target price for the company. Finally, Wall Street Zen upgraded shares of Kodiak Sciences from a "sell" rating to a "hold" rating in a research note on Friday, September 26th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $13.20.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.